Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single dose of an antipsychotic disrupt blood sugar control?

NCT ID NCT00910988

Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether a single dose of the antipsychotic drugs olanzapine or ziprasidone changes how the body responds to insulin, compared with a placebo. The study enrolls healthy young men who are overweight or have early signs of insulin resistance, but who have never taken antipsychotics. Researchers measure insulin sensitivity in the whole body, liver, muscle, and fat tissue to see if olanzapine, but not ziprasidone, causes an acute decrease. The findings could help explain why some antipsychotics raise the risk of diabetes and high blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olanzapine and ziprasidone, two antipsychotic drugs, compared against a placebo
What this could lead to
If olanzapine impairs insulin sensitivity more than ziprasidone, it could guide doctors toward antipsychotics with fewer metabolic side effects.
What could go wrong
This is a small, early-stage study in healthy men, not patients, so results may not reflect real-world use. The drugs may also cause drowsiness or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Start date

Feb 2009

Finished

Jun 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males aged 18-45 years * BMI approximately ≥ 25 and \< 35 * insulin approximately ≥ 15 µU/ml or triglyceride approximately ≥ 130 mg/dl Exclusion Criteria: * Any DSM-IV Axis I diagnosis * prisoners * any serious medical disorder (i.e. metabolic diseases, type 1 or 2 diabetes mellitus, endocrine disease, coagulopathy, clinically significant anemia, acute infection) * taking prescription medications * non-sedentary lifestyle with \> 3 hours of exercise per week

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperglycemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia hyperlipidemia Insulin Resistance multiple endocrine neoplasia type 1 Sedentary Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperglycemia Hyperlipidemia

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.